

SOARS score mortality								
0	1	2	3	4	5	6	7	8
1.4%	5.3%	5.9%	23.4%	35.4%	53.9%	72.5%	78.6%	>78.6%

### **INPATIENT MANAGEMENT**

Time/Date of initial treatment: \_\_\_\_\_/\_\_\_\_/ \_\_\_\_: \_\_\_\_ Name of clinician: \_\_\_\_\_\_

### 1. INITIAL TREATMENT

#### If RA SpO2<92% (unless COPD/OHS/CCF)

- ➔ Give supplemental oxygen target Sats up to 94%
- ➔ Prone if needed
- → Anticoagulation as per risk of VTE: Therapeutic/Prophylactic (see Anticoagulation and Thromboprophylaxis policy). CTPA to be considered after consultant/respiratory review
- → Perform PCT and **<u>STOP</u>** antibiotics if <u>below 0.25</u> mcg/L (Refer to MicroGuide)
  - 1. Send sputum sample and blood cultures
  - 2. Choice of antibiotics based on hospital guidelines (community acquired pneumonia; hospital acquired pneumonia; sepsis)
  - 3. Total duration of antibiotics 5 days
- ➔ Treat other comorbidities
- → Prescribe Covid medications if indicated (see medications on page 4)

### 2. CALCULATE CLINICAL FRAILTY SCORE (CFS) (PLEASE CIRCLE)

Your assessment should be based on the patient's functional status TWO WEEKS prior to hospitilisation



I Very Fit – People who are robust, active, energetic and motivated. These people commonly exercise regularly. They are among the fittest for their age.

2 Well – People who have no active disease symptoms but are less fit than category 1. Often, they exercise or are very active occasionally, e.g. seasonally.

3 Managing Well – People whose medical problems are well controlled, but are not regularly active beyond routine walking.



**4** Vulnerable – While not dependent on others for daily help, often symptoms limit activities. A common complaint is being "slowed up", and/or being tired during the day.



5 Mildly Frail – These people often have more evident slowing, and need help in high order IADLs (finances, transportation, heavy housework, medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation and housework.



6 Moderately Frail – People need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cuing, standby) with dressing.




7 Severely Frail – Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within ~ 6 months).

8 Very Severely Frail – Completely dependent, approaching the end of life. Typically, they could not recover even from a minor illness.



9. Terminally III - Approaching the end of life. This category applies to people with a life expectancy <6 months, who are not otherwise evidently frail.

### 3. MAKE ESCALATION DECISION AND DNACPR IF APPROPRIATE



## **FULL ESCALATION**

- If SpO<sub>2</sub> < 94% on FiO<sub>2</sub> of 0.6 or CPAP > 10cmH<sub>2</sub>O or PF ratio < 100 (PF ratio = arterial PaO<sub>2</sub> / FiO<sub>2</sub>) or worsening at 24h/daily review
  - → Rapid assessment for intubation & transfer to ITU if appropriate
- If SpO<sub>2</sub> < 94% on FiO<sub>2</sub> of 0.4
  - → Discuss with Respiratory Consultant (available 24hours) if candidate for NIV and recruitment into <u>Recovery Respiratory Support</u> as shown here:

Recovery Respiratory Support					
HIGH FLOW NASAL OXYGEN (HFNO)	CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP)	STANDARD CARE			
Start at 60L/min flow @ FiO <sub>2</sub> 0.6	Start at 8 cmH <sub>2</sub> O @ FiO2 0.5				
Up titrate by increasing $FiO_2$	Up titrate by increasing pressure by 2 or increasing FiO2	Based on clinical assessment			
<i>Weaning</i> Trial on Venturi face mask, if fails, back to HFNC	Weaning If FiO <sub>2</sub> <0.5 swap to A40 in CPAP mode with entrained O <sub>2</sub> to wean Match settings when swapped over Respiratory team review in one hour				

Assess daily clinical review; PF ratio; ABG; if deteriorating, discuss with Respiratory Consultant or ITU

# If SpO<sub>2</sub> > 94% on FiO<sub>2</sub> of 0.4 → Standard care in the ward

# WARD BASED CEILING OF CARE

- Always titrate treatment to maintain SpO<sub>2</sub> up to 94% (unless COPD/OHS/CCF where target is 88-92%)
- Therapeutic anticoagulation in ill patients with high suspicion for PE/DVT

### Not reaching SpO<sub>2</sub> up to 94% on FiO<sub>2</sub> of 0.4?

➔ Discuss with Respiratory Consultant in consideration of HFNO: Start at 60L/min flow @ FiO<sub>2</sub> 0.6 or CPAP (8 cmH<sub>2</sub>O @ FiO2 0.5)

### If PF ratio <100 or declining oxygenation or high risk score

→ Timely discussion with family to enable palliative support

# **MEDICATIONS – ACTIVE TREATMENT**

For more information about Covid-19 medications, contact Medicines Information.

		DEXAMETHASONE					
Indication	Treatment of Covid-19 on supplemental oxygen						
Dose	<ul> <li>6mg dexamethasone orally or 6.6mg dexamethasone IV, once a day, 7-10 days</li> <li>If on IV, switch to oral dexamethasone as soon as possible</li> <li>Dexamethasone should be stopped on discharge unless patient is hypoxic or still symptomatic and not at baseline, in which case the treatment course should be completed post discharge</li> <li>When prescribing dexamethasone consideration needs to be given to the gastric ulcer protection effect of proton pump inhibitors according to local hospital policy</li> </ul>						
The f	-	conclusive evidence – and should only be used with ro Consultant recommendation					
	REMDESIVIR	TOCILIZUMAB (discuss with Resp./ITU consultant)					
Indication	<ul> <li>Covid-19 confirmed, within acute viremic phase (after 7 days of symptom start)</li> <li>Lymphopenic</li> <li>Need for oxygenation but not requiring mechanical ventilation</li> <li>Ensure eGFR &gt;30; body weight &gt;40kg, and ALT &lt;200</li> <li>Day 1 – single loading dose of Remdesivir 200 mg given by</li> </ul>	<ul> <li>High dose methylprednisolone sparing agent targeting cytokine storm in critically ill confirmed COVID-19 patients at presentation with fever &gt;38 and Type 1 Respiratory failure due to pneumonia.</li> <li>And ONE or more of the following high-severity markers:         <ul> <li>CRP &gt;50/Ferritin &gt;500µg/L / D-dimer &gt;1000mg/ml / LDH &gt;250U/L</li> </ul> </li> <li>Exclusions:         <ul> <li>Known hypersensitivity to Tocilizumab</li> <li>Co-existing infection which may be worsened by Tocilizumab</li> <li>More than 24hrs on respiratory support</li> <li>Evidence of immunosuppression</li> <li>Platelets &lt;50x10<sup>9</sup>/L, ALT &gt;200, Neut. &lt;2 x10<sup>9</sup>/L</li> </ul> </li> </ul>					
Dose	intravenous infusion Day 2 onwards – 100 mg given once daily by IV infusion. <u>The total duration of treatment</u> <u>should be 5 days</u> Stop treatment if patient not on oxygen or discharged	<ul> <li>8mg/kg (up to a max. of 100kg) by IV</li> <li>Should be diluted in 100mL bag of 0.9% Sodium Chloride after removing equivalent volume of 0.9% Sodium Chloride and given over 1 hour</li> <li>A single dose to be administered with option to repeat dose in 12-24 hours if initial dose has not caused sufficient improvement</li> </ul>					

### **MEDICATIONS – PALLIATIVE CARE**

Indication	Drug	PRN S/C Dose	Syringe Driver (CSCI) over 24 hours
Pain/Cough	Morphine Sulphate (half dose	2.5-5mg 2-4 hourly	10-20mg
	in elderly patients. If eGFR		
	<30 use oxycodone)		
Breathlessness	Midazolam + Morphine	2.5-5mg 2-4 hourly	10mg
	sulphate (as above)		
Delirium	Haloperidol (half dose in	1-5mg in 1-3 divided doses	N/A
	elderly)	over 24h, max 5mg/day	
Delirium <i>if end of life</i>	Levomepromazine	25mg	50mg
	Midazolam	5mg 2-4 hourly	15mg
Nausea and Vomiting	Cyclizine	25mg 8 hourly	100-150mg
Seizures	Midazolam	5-10mg 2-4 hourly	30-60mg
Respiratory secretions	Glycopyrronium	0.2-0.4mg 4 hourly	1.2-2.4mg

#### If symptoms are not adequately controlled, please contact the palliative care team on 01923 217930 or bleep 1006

Version date: 29/01/2021 // Review date: 18/12/2021 // Version no: 5.1 // **Print Code: CovPath5.1** Authors: R. Vancheeswaran, A. Navarra, S. Khan, N. Nordin, R. Mogal, A, Jayarathnam, A. Barlow., CPG Prog. Page 4 of 4